Cardiovascular risk in chronic kidney disease: what is new in the pathogenesis and treatment?

7Citations
Citations of this article
27Readers
Mendeley users who have this article in their library.

You may have access to this PDF.

Abstract

The prevalence of chronic kidney disease (CKD) has increased markedly over past decades due to the aging of the worldwide population. Despite the progress in the prevention and treatment, the cardiovascular (CV) morbidity and mortality remain high among patients with CKD. Although CKD is a progressive and irreversible condition, it is possible to slow decreasing kidney function, as well as the development and progression of associated with kidney disease comorbidities. Diabetes mellitus has become major cause of CKD worldwide. It is estimated that the prevalence of diabetes will increase from 425 million worldwide in 2017 to 629 million by 2045, substantially the percentage of diabetic nephropathy among CKD patients is set to rise markedly. The results of multicenter trials concerning novel antidiabetic drugs suggest that efficacy in reducing CV risk is independent of the improvement in glycemic control. This review discusses underlying causes of high CV risk and strategies reducing individual burden among CKD patients.

Cite

CITATION STYLE

APA

Bazyluk, A., Malyszko, J., & Zbroch, E. (2018, July 4). Cardiovascular risk in chronic kidney disease: what is new in the pathogenesis and treatment? Postgraduate Medicine. Taylor and Francis Inc. https://doi.org/10.1080/00325481.2018.1481714

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free